KIR3DL1 and non-Hodgkin lymphoma: Further, investigation of clinical response to rituximab in 74 NHL patients demonstrated that low KIR ligand number and high frequency of KIR-positive NK cells, which are notably efficient in driving RTX-mediated ADCC, correlated with improved complete response (CR) and prognosis.